UK advises against covering Novartis’ Kymriah for adults; Ex-Mast chief Brian Culley appointed CEO at BioTime

→ Right on the heels of endorsing the use of Novartis’ CAR-T Kymriah in children, the UK drug price watchdog NICE is turning its thumbs down for extending its welcome to adults. “However, NICE does recognise that Novartis’ tisagenlecleucel-T, also known as Kymriah, has significant clinical benefits, and would welcome further discussions on its cost-effectiveness.”

→ Degenerative disease specialist BioTime $BTX has tapped Brian Culley as its new CEO, taking up a role previously shared by Adi Mohanty and Michael West. Culley helmed Mast Therapeutics for seven years before a failed lead program dragged it down and left it with little option other than serving as a shell for Savara’s reverse merger. West will now move onto the chief executive role at AgeX, a BioTime affiliate focused on age-related degenerative ailments.

→ Next-gen CAR-T company Tmunity has turned to the UK’s Abzena $ABZA for humanizing antibodies it needs for its programs.

Pharming’s application to expand the label for its hereditary angioedema drug has been spurned by regulators. The FDA is asking for an additional trial before it can consider Ruconest as a prophylactic treatment.

Roche is rolling out new apps designed to help support the way medical teams treat cancer patients.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->